Single-Agent PARP Inhibitors in Advanced Prostate Cancer

Comentario de un experto sobre las terapias de combinación que utilizan inhibidores de PARP más otros agentes en el cáncer de próstata avanzado de Clinical Care Options (CCO).

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: February 25, 2021

Commentaire des experts sur les associations thérapeutiques utilisant les inhibiteurs PARP et d'autres agents dans le traitement du cancer avancé de la prostate, extrait de Clinical Care Options (CCO)

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: February 25, 2021

Downloadable slideset with key highlight data from the virtual 2021 ASCO GU Cancers Symposium provided by Clinical Care Options (CCO)

Robert Motzer, MD Daniel P. Petrylak, MD Released: February 25, 2021

Downloadable slideset from Clinical Care Options (CCO) exploring early data and on ongoing clinical trials combining AR-directed therapy with PARP inhibition.

Neal D. Shore, MD, FACS Released: February 19, 2021